{"transactions":[{"id":767631,"issuer":{"id":5177,"kind":"organization","name":"Phathom Pharmaceuticals, Inc.","symbol":"PHAT"},"owners":[{"id":45159,"kind":"person","name":"KARBE FRANK","position":1,"cik":"0001276700","reported_name":"KARBE FRANK","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-21T20:30:05.000Z","date":"2026-05-19","kind":"grant","planned":false,"acquired":true,"shares":24122,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Restricted Stock Units (\"RSUs\") were granted on May 19, 2026, pursuant to the Issuer's Non-Employee Director Compensation Program. 100% of the total number of RSUs granted shall vest on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuing service on the Board through such vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer."}],"balance_after":91622,"source":{"system":"sec-edgar","filing":"0001193125-26-234564","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1276700/000119312526234564/ownership.xml","form_type":"4"}},{"id":944178,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":45159,"kind":"person","name":"KARBE FRANK","position":1,"cik":"0001276700","reported_name":"KARBE FRANK","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-01-08T01:16:00.000Z","date":"2026-01-07","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":115000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option."}],"balance_after":0,"derivative":{"exercise_price":20.5,"expiration_date":"2035-02-23","underlying":"Common Stock","underlying_shares":115000},"source":{"system":"sec-edgar","filing":"0001276700-26-000002","document":"wk-form4_1767834957.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1276700/000127670026000002/wk-form4_1767834957.xml","form_type":"4"}},{"id":944177,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":45159,"kind":"person","name":"KARBE FRANK","position":1,"cik":"0001276700","reported_name":"KARBE FRANK","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-01-08T01:16:00.000Z","date":"2026-01-07","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":43125,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding restricted stock unit award (\"RSU\"), whether vested or unvested, was cancelled and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to (i) the total number of Common Shares issuable in settlement of such RSU immediately prior to the effective time of the Merger multiplied by (ii) $221.50 per Common Share."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding restricted stock unit award (\"RSU\"), whether vested or unvested, was cancelled and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to (i) the total number of Common Shares issuable in settlement of such RSU immediately prior to the effective time of the Merger multiplied by (ii) $221.50 per Common Share."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001276700-26-000002","document":"wk-form4_1767834957.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1276700/000127670026000002/wk-form4_1767834957.xml","form_type":"4"}},{"id":944176,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":45159,"kind":"person","name":"KARBE FRANK","position":1,"cik":"0001276700","reported_name":"KARBE FRANK","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-01-08T01:16:00.000Z","date":"2026-01-07","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":7526,"price":221.5,"value":1667009.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated November 13, 2025, by and among Cidara Therapeutics, Inc. (the \"Issuer\"), Merck Sharp & Dohme LLC (\"Merck\") and Caymus Purchaser, Inc., a wholly owned subsidiary of Merck (\"Purchaser\"), on January 7, 2026, Purchaser completed a tender offer to acquire (i) all outstanding shares of common stock of the Issuer, par value $0.0001 per share (each, a \"Common Share\") and (ii) all outstanding shares of Series A Convertible Voting Preferred Stock of the Issuer, par value $0.0001 per share (each, a \"Series A Share\"), and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Merck (the \"Merger\"). [continues to Footnote 2]"},{"field":"kind","element":"transactionCoding","label":"F2","text":"[continues from Footnote 1] Pursuant to the terms of the Merger Agreement, Common Shares and Series A Shares were tendered and disposed of at the Offer Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive (i) $221.50 per Common Share (the \"Common Share Merger Consideration\"), in cash, without interest, subject to any applicable withholding of taxes, and (ii) $15,505.00 per Series A Share (the \"Series A Merger Consideration\"), in cash, without interest, subject to any applicable withholding of taxes. [continues to Footnote 3]"},{"field":"kind","element":"transactionCoding","label":"F3","text":"[continues from Footnote 2] At the effective time of the Merger, each issued and outstanding Common Share and Series A Share (other than Common Shares (a) held by the Issuer (or in the Issuer's treasury), Merck, Purchaser, any other direct or indirect wholly owned subsidiary of Merck or the Issuer, or by stockholders of the Issuer who have properly exercised and perfected their statutory rights of appraisal, or (b) irrevocably accepted for purchase in the tender offer) was automatically canceled and converted into the right to receive the Common Share Merger Consideration and the Series A Merger Consideration, respectively, without interest and subject to any applicable withholding of taxes."},{"field":"shares","element":"transactionShares","label":"F4","text":"Includes 89 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan (ESPP) on December 18, 2025."}],"balance_after":43125,"source":{"system":"sec-edgar","filing":"0001276700-26-000002","document":"wk-form4_1767834957.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1276700/000127670026000002/wk-form4_1767834957.xml","form_type":"4"}},{"id":970930,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":45159,"kind":"person","name":"KARBE FRANK","position":1,"cik":"0001276700","reported_name":"KARBE FRANK","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-12-13T00:41:47.000Z","date":"2025-12-10","kind":"tax_withholding","planned":false,"acquired":false,"shares":7290,"price":219.6,"value":1600884.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares withheld for taxes on RSU vesting."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 352 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan (ESPP) on November 20, 2025."}],"balance_after":50562,"source":{"system":"sec-edgar","filing":"0001610618-25-000102","document":"wk-form4_1765586504.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1276700/000161061825000102/wk-form4_1765586504.xml","form_type":"4"}},{"id":1121035,"issuer":{"id":5177,"kind":"organization","name":"Phathom Pharmaceuticals, Inc.","symbol":"PHAT"},"owners":[{"id":45159,"kind":"person","name":"KARBE FRANK","position":1,"cik":"0001276700","reported_name":"KARBE FRANK","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-05T20:58:25.000Z","date":"2025-06-03","kind":"grant","planned":false,"acquired":true,"shares":17500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. The option shall vest and/or become exercisable on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to Reporting Person's continuing in service on the Board through such vesting date."}],"balance_after":17500,"derivative":{"exercise_price":4.95,"expiration_date":"2035-06-02","underlying":"Common Stock","underlying_shares":17500},"source":{"system":"sec-edgar","filing":"0000950170-25-082458","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1276700/000095017025082458/ownership.xml","form_type":"4"}},{"id":1121034,"issuer":{"id":5177,"kind":"organization","name":"Phathom Pharmaceuticals, Inc.","symbol":"PHAT"},"owners":[{"id":45159,"kind":"person","name":"KARBE FRANK","position":1,"cik":"0001276700","reported_name":"KARBE FRANK","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-05T20:58:25.000Z","date":"2025-06-03","kind":"grant","planned":false,"acquired":true,"shares":10500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Restricted Stock Units (\"RSUs\") were granted on June 3, 2025, pursuant to the Issuer's Non-Employee Director Compensation Program. 100% of the total number of RSUs granted shall vest on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuing service on the Board through such vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer."}],"balance_after":67500,"source":{"system":"sec-edgar","filing":"0000950170-25-082458","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1276700/000095017025082458/ownership.xml","form_type":"4"}},{"id":1242634,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":45159,"kind":"person","name":"KARBE FRANK","position":1,"cik":"0001276700","reported_name":"KARBE FRANK","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-02-26T23:31:07.000Z","date":"2025-02-24","kind":"grant","planned":false,"acquired":true,"shares":115000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares subject to the option shall vest on the 1st anniversary of the vesting commencement date of February 24, 2025, and the balance of the shares shall vest in a series of 36 equal monthly installments measured from the 1st anniversary of the vesting commencement date, such that the option will be fully vested on February 24, 2029, subject to continuous service through each such vesting date."}],"balance_after":115000,"derivative":{"exercise_price":20.5,"expiration_date":"2035-02-23","underlying":"Common Stock","underlying_shares":115000},"source":{"system":"sec-edgar","filing":"0001610618-25-000012","document":"wk-form4_1740612660.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1276700/000161061825000012/wk-form4_1740612660.xml","form_type":"4"}},{"id":1242633,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":45159,"kind":"person","name":"KARBE FRANK","position":1,"cik":"0001276700","reported_name":"KARBE FRANK","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-02-26T23:31:07.000Z","date":"2025-02-24","kind":"grant","planned":false,"acquired":true,"shares":57500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents time-based Restricted Stock Units (RSUs) granted on February 24, 2025. All RSUs vest in four equal annual installments, with 1/4 vesting on each of March 10, 2026, 2027, 2028, and 2029, subject to continuous service through each such vesting date."}],"balance_after":57500,"source":{"system":"sec-edgar","filing":"0001610618-25-000012","document":"wk-form4_1740612660.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1276700/000161061825000012/wk-form4_1740612660.xml","form_type":"4"}},{"id":1330616,"issuer":{"id":5177,"kind":"organization","name":"Phathom Pharmaceuticals, Inc.","symbol":"PHAT"},"owners":[{"id":45159,"kind":"person","name":"KARBE FRANK","position":1,"cik":"0001276700","reported_name":"KARBE FRANK","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-12-16T13:05:06.000Z","date":"2024-12-13","kind":"purchase","planned":false,"acquired":true,"shares":12500,"price":7.9267,"value":99083.75,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.87 to $8.00. The reporting person undertakes to provide Phathom Pharmaceuticals, Inc. (the \"Company\"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":57000,"source":{"system":"sec-edgar","filing":"0000950170-24-136391","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1276700/000095017024136391/ownership.xml","form_type":"4"}},{"id":1496399,"issuer":{"id":5177,"kind":"organization","name":"Phathom Pharmaceuticals, Inc.","symbol":"PHAT"},"owners":[{"id":45159,"kind":"person","name":"KARBE FRANK","position":1,"cik":"0001276700","reported_name":"KARBE FRANK","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-05-31T20:30:28.000Z","date":"2024-05-29","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":10.1645,"value":254112.5,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.1016 to $10.20. The reporting person undertakes to provide Phathom Pharmaceuticals, Inc. (the \"Company\"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":44500,"source":{"system":"sec-edgar","filing":"0000950170-24-067365","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1276700/000095017024067365/ownership.xml","form_type":"4"}},{"id":1501713,"issuer":{"id":5177,"kind":"organization","name":"Phathom Pharmaceuticals, Inc.","symbol":"PHAT"},"owners":[{"id":45159,"kind":"person","name":"KARBE FRANK","position":1,"cik":"0001276700","reported_name":"KARBE FRANK","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-05-24T23:33:56.000Z","date":"2024-05-23","kind":"grant","planned":false,"acquired":false,"shares":17500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. The option shall vest and/or become exercisable on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to Reporting Person's continuing in service on the Board through such vesting date."}],"balance_after":17500,"derivative":{"exercise_price":10.3,"expiration_date":"2034-05-22","underlying":"Common Stock","underlying_shares":17500},"source":{"system":"sec-edgar","filing":"0000950170-24-064820","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1276700/000095017024064820/ownership.xml","form_type":"4"}},{"id":1501712,"issuer":{"id":5177,"kind":"organization","name":"Phathom Pharmaceuticals, Inc.","symbol":"PHAT"},"owners":[{"id":45159,"kind":"person","name":"KARBE FRANK","position":1,"cik":"0001276700","reported_name":"KARBE FRANK","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-05-24T23:33:56.000Z","date":"2024-05-23","kind":"grant","planned":false,"acquired":true,"shares":10500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Restricted Stock Units (\"RSUs\") were granted on May 23, 2024, pursuant to the Issuer's Non-Employee Director Compensation Program. 100% of the total number of RSUs granted shall vest on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuing service on the Board through such vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer."}],"balance_after":19500,"source":{"system":"sec-edgar","filing":"0000950170-24-064820","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1276700/000095017024064820/ownership.xml","form_type":"4"}},{"id":1703223,"issuer":{"id":94385,"kind":"organization","name":"Better Therapeutics, Inc.","symbol":"BTTX"},"owners":[{"id":45159,"kind":"person","name":"KARBE FRANK","position":1,"cik":"0001276700","reported_name":"KARBE FRANK","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-12-20T22:13:55.000Z","date":"2023-12-18","kind":"grant","planned":false,"acquired":true,"shares":62500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting person was awarded 62,500 Restricted Stock Units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest on June 1, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 34,587 shares acquired under the Issuer's 2021 Employee Stock Purchase Plan on November 30, 2023."}],"balance_after":526516,"source":{"system":"sec-edgar","filing":"0000950170-23-071939","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1276700/000095017023071939/ownership.xml","form_type":"4"}},{"id":1820334,"issuer":{"id":94385,"kind":"organization","name":"Better Therapeutics, Inc.","symbol":"BTTX"},"owners":[{"id":45159,"kind":"person","name":"KARBE FRANK","position":1,"cik":"0001276700","reported_name":"KARBE FRANK","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-07-31T11:58:47.000Z","date":"2023-07-27","kind":"purchase","planned":false,"acquired":true,"shares":137005,"price":0.7299,"value":99999.9495,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 25, 2023, the Issuer entered into a Securities Purchase Agreement with certain investors (the \"PIPE Investors\") in a private placement offering, pursuant to which the PIPE Investors agreed to purchase shares of Issuer common stock for $0.7299 per share."},{"field":"kind","element":"transactionCoding","label":"F2","text":"As one of the PIPE Investors, the Reporting Person acquired 137,005 shares of Issuer common stock on July 27, 2023 for $0.7299 per share."}],"balance_after":429429,"source":{"system":"sec-edgar","filing":"0000950170-23-035680","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1276700/000095017023035680/ownership.xml","form_type":"4"}},{"id":1874460,"issuer":{"id":5177,"kind":"organization","name":"Phathom Pharmaceuticals, Inc.","symbol":"PHAT"},"owners":[{"id":45159,"kind":"person","name":"KARBE FRANK","position":1,"cik":"0001276700","reported_name":"KARBE FRANK","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-30T22:48:32.000Z","date":"2023-05-25","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. The option shall vest and/or become exercisable on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuing in service on the Board through such vesting date."}],"balance_after":15000,"derivative":{"exercise_price":11.72,"expiration_date":"2033-05-24","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-23-033007","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1276700/000120919123033007/doc4.xml","form_type":"4"}},{"id":1874459,"issuer":{"id":5177,"kind":"organization","name":"Phathom Pharmaceuticals, Inc.","symbol":"PHAT"},"owners":[{"id":45159,"kind":"person","name":"KARBE FRANK","position":1,"cik":"0001276700","reported_name":"KARBE FRANK","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-05-30T22:48:32.000Z","date":"2023-05-25","kind":"grant","planned":false,"acquired":true,"shares":9000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Restricted Stock Units (\"RSUs\") were granted on May 25, 2023, pursuant to the Issuer's Non-Employee Director Compensation Program. 100% of the total number of RSUs granted shall vest on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuing service on the Board through such vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer."}],"balance_after":9000,"source":{"system":"sec-edgar","filing":"0001209191-23-033007","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1276700/000120919123033007/doc4.xml","form_type":"4"}},{"id":1920823,"issuer":{"id":94385,"kind":"organization","name":"Better Therapeutics, Inc.","symbol":"BTTX"},"owners":[{"id":45159,"kind":"person","name":"KARBE FRANK","position":1,"cik":"0001276700","reported_name":"KARBE FRANK","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2023-04-12T20:15:14.000Z","date":"2023-04-10","kind":"purchase","planned":false,"acquired":true,"shares":242424,"price":0.825,"value":199999.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On April 6, 2023, the Issuer entered into a Securities Purchase Agreement with certain investors (the \"PIPE Investors\") in a private placement offering, pursuant to which the PIPE Investors agreed to purchase shares of Issuer common stock for $0.825 per share. As one of the PIPE Investors, the Reporting Person acquired 242,424 shares of Issuer common stock on April 10, 2023 for $0.825 per share."}],"balance_after":292424,"source":{"system":"sec-edgar","filing":"0000899243-23-011189","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1276700/000089924323011189/doc4.xml","form_type":"4"}},{"id":2158251,"issuer":{"id":94385,"kind":"organization","name":"Better Therapeutics, Inc.","symbol":"BTTX"},"owners":[{"id":45159,"kind":"person","name":"KARBE FRANK","position":1,"cik":"0001276700","reported_name":"KARBE FRANK","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2022-09-16T00:53:54.000Z","date":"2022-09-15","kind":"purchase","acquired":true,"shares":50000,"price":2.0939,"value":104695.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.06 to $2.10, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":50000,"source":{"system":"sec-edgar","filing":"0000899243-22-031206","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1276700/000089924322031206/doc4.xml","form_type":"4"}},{"id":2210605,"issuer":{"id":94385,"kind":"organization","name":"Better Therapeutics, Inc.","symbol":"BTTX"},"owners":[{"id":45159,"kind":"person","name":"KARBE FRANK","position":1,"cik":"0001276700","reported_name":"KARBE FRANK","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-07-07T20:32:20.000Z","date":"2022-07-05","kind":"grant","acquired":true,"shares":472200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to 1/4 of the shares subject to the stock option on July 5, 2023 and the remaining shares vest in 36 equal monthly installments thereafter, provided the Reporting Person continues to have a service relationship with Issuer on each vesting date. The stock option was granted on July 5, 2022."}],"balance_after":472200,"derivative":{"exercise_price":1.68,"expiration_date":"2032-07-04","underlying":"Common Stock","underlying_shares":472200},"source":{"system":"sec-edgar","filing":"0000899243-22-025715","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1276700/000089924322025715/doc4.xml","form_type":"4"}},{"id":2252964,"issuer":{"id":5177,"kind":"organization","name":"Phathom Pharmaceuticals, Inc.","symbol":"PHAT"},"owners":[{"id":45159,"kind":"person","name":"KARBE FRANK","position":1,"cik":"0001276700","reported_name":"KARBE FRANK","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-05-27T20:41:31.000Z","date":"2022-05-25","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will vest with respect to one-third of the shares of common stock on April 25, 2023, and will vest in substantially equal quarterly installments over the twenty-four (24) months thereafter, subject to the Reporting Person's continuous service to the Issuer on the applicable vesting dates."}],"balance_after":10000,"derivative":{"exercise_price":7.4,"expiration_date":"2032-05-24","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-22-032578","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1276700/000120919122032578/doc4.xml","form_type":"4"}},{"id":2290212,"issuer":{"id":5177,"kind":"organization","name":"Phathom Pharmaceuticals, Inc.","symbol":"PHAT"},"owners":[{"id":45159,"kind":"person","name":"KARBE FRANK","position":1,"cik":"0001276700","reported_name":"KARBE FRANK","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-04-26T21:21:46.000Z","date":"2022-04-25","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will vest with respect to one-third of the shares of common stock on April 25, 2023, and will vest in substantially equal quarterly installments over the twenty-four (24) months thereafter, subject to the reporting person's continuous service to the Issuer on the applicable vesting dates."}],"balance_after":20000,"derivative":{"exercise_price":13.61,"expiration_date":"2032-04-24","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-22-025660","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1276700/000120919122025660/doc4.xml","form_type":"4"}},{"id":2636854,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":45159,"kind":"person","name":"KARBE FRANK","position":1,"cik":"0001276700","reported_name":"KARBE FRANK","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Fin'l & Accounting"}}],"security":"Common Shares","published_at":"2021-07-09T20:27:07.000Z","date":"2021-07-07","kind":"sale","acquired":false,"shares":3232,"price":21.75,"value":70296.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares sold by the reporting person to cover the tax obligation realized upon the vesting of restricted stock units previously reported in Table I."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The shares were sold at prices ranging from $21.75 to $21.83. The reporting person will provide to the SEC, the issuer or security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":212296,"source":{"system":"sec-edgar","filing":"0001209191-21-046171","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1276700/000120919121046171/doc4.xml","form_type":"4"}},{"id":2744864,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":45159,"kind":"person","name":"KARBE FRANK","position":1,"cik":"0001276700","reported_name":"KARBE FRANK","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Fin'l & Accounting"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-04-19T20:17:47.000Z","date":"2021-04-15","kind":"grant","acquired":true,"shares":97534,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/4 of the common shares underlying this option vest on April 15, 2022, and 1/16 of the common shares underlying this option vest each quarter thereafter, provided the Reporting Person has provided continuous service to the Issuer or its affiliates on each such date."}],"balance_after":97534,"derivative":{"exercise_price":17.88,"expiration_date":"2031-04-14","underlying":"Common Shares","underlying_shares":97534},"source":{"system":"sec-edgar","filing":"0001209191-21-027281","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1276700/000120919121027281/doc4.xml","form_type":"4"}},{"id":2744863,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":45159,"kind":"person","name":"KARBE FRANK","position":1,"cik":"0001276700","reported_name":"KARBE FRANK","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Fin'l & Accounting"}}],"security":"Common Shares","published_at":"2021-04-19T20:17:47.000Z","date":"2021-04-15","kind":"grant","acquired":true,"shares":63138,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Common Shares are to be acquired upon the vesting of certain Restricted Stock Units (\"RSUs\") granted to the Reporting Person. 1/4 of the common shares underlying the RSUs vest on April 15, 2022, and 1/16 of the common shares underlying the RSUs vest each quarter thereafter, provided the Reporting Person has provided continuous service to the Issuer or its affiliates on each such date."}],"balance_after":215528,"source":{"system":"sec-edgar","filing":"0001209191-21-027281","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1276700/000120919121027281/doc4.xml","form_type":"4"}},{"id":2752806,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":45159,"kind":"person","name":"KARBE FRANK","position":1,"cik":"0001276700","reported_name":"KARBE FRANK","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Fin'l & Accounting"}}],"security":"Common Shares","published_at":"2021-04-08T20:55:04.000Z","date":"2021-04-06","kind":"sale","acquired":false,"shares":11080,"price":18.63,"value":206420.4,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares sold by the reporting person to cover the tax obligation realized upon the vesting of restricted stock units previously reported in Table I."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The shares were sold at prices ranging from $18.60 to $19.04. The reporting person will provide to the SEC, the issuer or security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":152390,"source":{"system":"sec-edgar","filing":"0001209191-21-026084","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1276700/000120919121026084/doc4.xml","form_type":"4"}},{"id":2849283,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":45159,"kind":"person","name":"KARBE FRANK","position":1,"cik":"0001276700","reported_name":"KARBE FRANK","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Fin'l & Accounting"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-02-18T21:52:53.000Z","date":"2021-02-16","kind":"exercise","acquired":false,"shares":750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Fully vested."}],"balance_after":181744,"derivative":{"exercise_price":5.11,"expiration_date":"2026-09-20","underlying":"Common Shares","underlying_shares":750},"source":{"system":"sec-edgar","filing":"0001209191-21-011894","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1276700/000120919121011894/doc4.xml","form_type":"4"}},{"id":2849282,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":45159,"kind":"person","name":"KARBE FRANK","position":1,"cik":"0001276700","reported_name":"KARBE FRANK","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Fin'l & Accounting"}}],"security":"Common Shares","published_at":"2021-02-18T21:52:53.000Z","date":"2021-02-16","kind":"sale","acquired":false,"shares":750,"price":21.4,"value":16050.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares sold pursuant to a 10b5-1 trading plan."}],"balance_after":163470,"source":{"system":"sec-edgar","filing":"0001209191-21-011894","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1276700/000120919121011894/doc4.xml","form_type":"4"}},{"id":2849281,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":45159,"kind":"person","name":"KARBE FRANK","position":1,"cik":"0001276700","reported_name":"KARBE FRANK","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Fin'l & Accounting"}}],"security":"Common Shares","published_at":"2021-02-18T21:52:53.000Z","date":"2021-02-16","kind":"exercise","acquired":true,"shares":750,"price":5.11,"value":3832.5,"ownership":{"direct":true},"balance_after":164220,"source":{"system":"sec-edgar","filing":"0001209191-21-011894","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1276700/000120919121011894/doc4.xml","form_type":"4"}},{"id":2888373,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":45159,"kind":"person","name":"KARBE FRANK","position":1,"cik":"0001276700","reported_name":"KARBE FRANK","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Fin'l & Accounting"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-02-01T21:29:31.000Z","date":"2021-01-28","kind":"exercise","acquired":false,"shares":300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Fully vested."}],"balance_after":182494,"derivative":{"exercise_price":5.11,"expiration_date":"2026-09-20","underlying":"Common Shares","underlying_shares":300},"source":{"system":"sec-edgar","filing":"0001209191-21-006444","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1276700/000120919121006444/doc4.xml","form_type":"4"}},{"id":2888372,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":45159,"kind":"person","name":"KARBE FRANK","position":1,"cik":"0001276700","reported_name":"KARBE FRANK","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Fin'l & Accounting"}}],"security":"Common Shares","published_at":"2021-02-01T21:29:31.000Z","date":"2021-01-28","kind":"sale","acquired":false,"shares":300,"price":24,"value":7200.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares sold pursuant to a 10b5-1 trading plan."}],"balance_after":163470,"source":{"system":"sec-edgar","filing":"0001209191-21-006444","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1276700/000120919121006444/doc4.xml","form_type":"4"}},{"id":2888371,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":45159,"kind":"person","name":"KARBE FRANK","position":1,"cik":"0001276700","reported_name":"KARBE FRANK","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Fin'l & Accounting"}}],"security":"Common Shares","published_at":"2021-02-01T21:29:31.000Z","date":"2021-01-28","kind":"exercise","acquired":true,"shares":300,"price":5.11,"value":1533.0,"ownership":{"direct":true},"balance_after":163770,"source":{"system":"sec-edgar","filing":"0001209191-21-006444","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1276700/000120919121006444/doc4.xml","form_type":"4"}},{"id":2901844,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":45159,"kind":"person","name":"KARBE FRANK","position":1,"cik":"0001276700","reported_name":"KARBE FRANK","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Fin'l & Accounting"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-01-20T21:39:32.000Z","date":"2021-01-15","kind":"exercise","acquired":false,"shares":750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Fully vested."}],"balance_after":182794,"derivative":{"exercise_price":5.11,"expiration_date":"2026-09-20","underlying":"Common Shares","underlying_shares":750},"source":{"system":"sec-edgar","filing":"0001209191-21-004328","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1276700/000120919121004328/doc4.xml","form_type":"4"}},{"id":2901843,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":45159,"kind":"person","name":"KARBE FRANK","position":1,"cik":"0001276700","reported_name":"KARBE FRANK","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Fin'l & Accounting"}}],"security":"Common Shares","published_at":"2021-01-20T21:39:32.000Z","date":"2021-01-15","kind":"sale","acquired":false,"shares":750,"price":21.5,"value":16125.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares sold pursuant to a 10b5-1 trading plan."}],"balance_after":163470,"source":{"system":"sec-edgar","filing":"0001209191-21-004328","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1276700/000120919121004328/doc4.xml","form_type":"4"}},{"id":2901842,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":45159,"kind":"person","name":"KARBE FRANK","position":1,"cik":"0001276700","reported_name":"KARBE FRANK","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Fin'l & Accounting"}}],"security":"Common Shares","published_at":"2021-01-20T21:39:32.000Z","date":"2021-01-15","kind":"exercise","acquired":true,"shares":750,"price":5.11,"value":3832.5,"ownership":{"direct":true},"balance_after":164220,"source":{"system":"sec-edgar","filing":"0001209191-21-004328","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1276700/000120919121004328/doc4.xml","form_type":"4"}},{"id":2928600,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":45159,"kind":"person","name":"KARBE FRANK","position":1,"cik":"0001276700","reported_name":"KARBE FRANK","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Fin'l & Accounting"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-12-30T21:29:10.000Z","date":"2020-12-28","kind":"exercise","acquired":false,"shares":11800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Fully vested."}],"balance_after":183544,"derivative":{"exercise_price":5.11,"expiration_date":"2026-09-20","underlying":"Common Shares","underlying_shares":11800},"source":{"system":"sec-edgar","filing":"0001209191-20-065511","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1276700/000120919120065511/doc4.xml","form_type":"4"}},{"id":2928599,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":45159,"kind":"person","name":"KARBE FRANK","position":1,"cik":"0001276700","reported_name":"KARBE FRANK","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Fin'l & Accounting"}}],"security":"Common Shares","published_at":"2020-12-30T21:29:10.000Z","date":"2020-12-28","kind":"sale","acquired":false,"shares":11800,"price":30,"value":354000.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares sold pursuant to a 10b5-1 trading plan."}],"balance_after":163470,"source":{"system":"sec-edgar","filing":"0001209191-20-065511","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1276700/000120919120065511/doc4.xml","form_type":"4"}},{"id":2928598,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":45159,"kind":"person","name":"KARBE FRANK","position":1,"cik":"0001276700","reported_name":"KARBE FRANK","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Fin'l & Accounting"}}],"security":"Common Shares","published_at":"2020-12-30T21:29:10.000Z","date":"2020-12-28","kind":"exercise","acquired":true,"shares":11800,"price":5.11,"value":60298.0,"ownership":{"direct":true},"balance_after":175270,"source":{"system":"sec-edgar","filing":"0001209191-20-065511","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1276700/000120919120065511/doc4.xml","form_type":"4"}},{"id":2939652,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":45159,"kind":"person","name":"KARBE FRANK","position":1,"cik":"0001276700","reported_name":"KARBE FRANK","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Fin'l & Accounting"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-12-17T21:51:09.000Z","date":"2020-12-15","kind":"exercise","acquired":false,"shares":1050,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Fully vested."}],"balance_after":195344,"derivative":{"exercise_price":5.11,"expiration_date":"2026-09-20","underlying":"Common Shares","underlying_shares":1050},"source":{"system":"sec-edgar","filing":"0001209191-20-064096","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1276700/000120919120064096/doc4.xml","form_type":"4"}},{"id":2939651,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":45159,"kind":"person","name":"KARBE FRANK","position":1,"cik":"0001276700","reported_name":"KARBE FRANK","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Fin'l & Accounting"}}],"security":"Common Stock","published_at":"2020-12-17T21:51:09.000Z","date":"2020-12-15","kind":"sale","acquired":false,"shares":670,"price":24.4515,"value":16382.505,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares sold pursuant to a 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The shares were sold at prices ranging from $24.05 to $24.75. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":163470,"source":{"system":"sec-edgar","filing":"0001209191-20-064096","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1276700/000120919120064096/doc4.xml","form_type":"4"}},{"id":2939650,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":45159,"kind":"person","name":"KARBE FRANK","position":1,"cik":"0001276700","reported_name":"KARBE FRANK","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Fin'l & Accounting"}}],"security":"Common Shares","published_at":"2020-12-17T21:51:09.000Z","date":"2020-12-15","kind":"sale","acquired":false,"shares":380,"price":23.6321,"value":8980.198,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares sold pursuant to a 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The shares were sold at prices ranging from $23.05 to $24.03. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":164140,"source":{"system":"sec-edgar","filing":"0001209191-20-064096","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1276700/000120919120064096/doc4.xml","form_type":"4"}},{"id":2939649,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":45159,"kind":"person","name":"KARBE FRANK","position":1,"cik":"0001276700","reported_name":"KARBE FRANK","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Fin'l & Accounting"}}],"security":"Common Shares","published_at":"2020-12-17T21:51:09.000Z","date":"2020-12-15","kind":"exercise","acquired":true,"shares":1050,"price":5.11,"value":5365.5,"ownership":{"direct":true},"balance_after":164520,"source":{"system":"sec-edgar","filing":"0001209191-20-064096","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1276700/000120919120064096/doc4.xml","form_type":"4"}},{"id":2960320,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":45159,"kind":"person","name":"KARBE FRANK","position":1,"cik":"0001276700","reported_name":"KARBE FRANK","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Fin'l & Accounting"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-12-02T22:08:29.000Z","date":"2020-11-30","kind":"exercise","acquired":false,"shares":1500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Fully vested."}],"balance_after":196394,"derivative":{"exercise_price":5.11,"expiration_date":"2026-09-20","underlying":"Common Shares","underlying_shares":1500},"source":{"system":"sec-edgar","filing":"0001209191-20-061221","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1276700/000120919120061221/doc4.xml","form_type":"4"}},{"id":2960319,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":45159,"kind":"person","name":"KARBE FRANK","position":1,"cik":"0001276700","reported_name":"KARBE FRANK","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Fin'l & Accounting"}}],"security":"Common Shares","published_at":"2020-12-02T22:08:29.000Z","date":"2020-11-30","kind":"sale","acquired":false,"shares":1500,"price":24,"value":36000.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares sold pursuant to a 10b5-1 trading plan."}],"balance_after":163470,"source":{"system":"sec-edgar","filing":"0001209191-20-061221","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1276700/000120919120061221/doc4.xml","form_type":"4"}},{"id":2960318,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":45159,"kind":"person","name":"KARBE FRANK","position":1,"cik":"0001276700","reported_name":"KARBE FRANK","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Fin'l & Accounting"}}],"security":"Common Shares","published_at":"2020-12-02T22:08:29.000Z","date":"2020-11-30","kind":"exercise","acquired":true,"shares":1500,"price":5.11,"value":7665.0,"ownership":{"direct":true},"balance_after":164970,"source":{"system":"sec-edgar","filing":"0001209191-20-061221","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1276700/000120919120061221/doc4.xml","form_type":"4"}},{"id":2972871,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":45159,"kind":"person","name":"KARBE FRANK","position":1,"cik":"0001276700","reported_name":"KARBE FRANK","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Fin'l & Accounting"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-11-19T22:04:03.000Z","date":"2020-11-17","kind":"exercise","acquired":false,"shares":750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Fully vested."}],"balance_after":197894,"derivative":{"exercise_price":5.11,"expiration_date":"2026-09-20","underlying":"Common Shares","underlying_shares":750},"source":{"system":"sec-edgar","filing":"0001209191-20-059450","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1276700/000120919120059450/doc4.xml","form_type":"4"}},{"id":2972870,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":45159,"kind":"person","name":"KARBE FRANK","position":1,"cik":"0001276700","reported_name":"KARBE FRANK","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Fin'l & Accounting"}}],"security":"Common Shares","published_at":"2020-11-19T22:04:03.000Z","date":"2020-11-17","kind":"sale","acquired":false,"shares":750,"price":20,"value":15000.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares sold pursuant to a 10b5-1 trading plan."}],"balance_after":163470,"source":{"system":"sec-edgar","filing":"0001209191-20-059450","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1276700/000120919120059450/doc4.xml","form_type":"4"}},{"id":2972869,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":45159,"kind":"person","name":"KARBE FRANK","position":1,"cik":"0001276700","reported_name":"KARBE FRANK","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Fin'l & Accounting"}}],"security":"Common Shares","published_at":"2020-11-19T22:04:03.000Z","date":"2020-11-17","kind":"exercise","acquired":true,"shares":750,"price":5.11,"value":3832.5,"ownership":{"direct":true},"balance_after":164220,"source":{"system":"sec-edgar","filing":"0001209191-20-059450","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1276700/000120919120059450/doc4.xml","form_type":"4"}},{"id":2977210,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":45159,"kind":"person","name":"KARBE FRANK","position":1,"cik":"0001276700","reported_name":"KARBE FRANK","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Fin'l & Accounting"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-11-17T23:50:51.000Z","date":"2020-11-13","kind":"exercise","acquired":false,"shares":750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Fully vested."}],"balance_after":198644,"derivative":{"exercise_price":5.11,"expiration_date":"2026-09-20","underlying":"Common Shares","underlying_shares":750},"source":{"system":"sec-edgar","filing":"0001209191-20-058894","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1276700/000120919120058894/doc4.xml","form_type":"4"}},{"id":2977209,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":45159,"kind":"person","name":"KARBE FRANK","position":1,"cik":"0001276700","reported_name":"KARBE FRANK","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Fin'l & Accounting"}}],"security":"Common Shares","published_at":"2020-11-17T23:50:51.000Z","date":"2020-11-13","kind":"sale","acquired":false,"shares":750,"price":20,"value":15000.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares sold pursuant to a 10b5-1 trading plan."}],"balance_after":163470,"source":{"system":"sec-edgar","filing":"0001209191-20-058894","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1276700/000120919120058894/doc4.xml","form_type":"4"}},{"id":2977208,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":45159,"kind":"person","name":"KARBE FRANK","position":1,"cik":"0001276700","reported_name":"KARBE FRANK","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Fin'l & Accounting"}}],"security":"Common Shares","published_at":"2020-11-17T23:50:51.000Z","date":"2020-11-13","kind":"exercise","acquired":true,"shares":750,"price":5.11,"value":3832.5,"ownership":{"direct":true},"balance_after":164220,"source":{"system":"sec-edgar","filing":"0001209191-20-058894","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1276700/000120919120058894/doc4.xml","form_type":"4"}},{"id":3027966,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":45159,"kind":"person","name":"KARBE FRANK","position":1,"cik":"0001276700","reported_name":"KARBE FRANK","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Fin'l & Accounting"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-09-17T20:20:15.000Z","date":"2020-09-15","kind":"exercise","acquired":false,"shares":750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Fully vested."}],"balance_after":199394,"derivative":{"exercise_price":5.11,"expiration_date":"2026-09-20","underlying":"Common Shares","underlying_shares":750},"source":{"system":"sec-edgar","filing":"0001209191-20-050887","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1276700/000120919120050887/doc4.xml","form_type":"4"}},{"id":3027965,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":45159,"kind":"person","name":"KARBE FRANK","position":1,"cik":"0001276700","reported_name":"KARBE FRANK","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Fin'l & Accounting"}}],"security":"Common Shares","published_at":"2020-09-17T20:20:15.000Z","date":"2020-09-15","kind":"sale","acquired":false,"shares":750,"price":21.73,"value":16297.5,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares sold pursuant to a 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The shares were sold at prices ranging from $21.46 to $21.97. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":163470,"source":{"system":"sec-edgar","filing":"0001209191-20-050887","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1276700/000120919120050887/doc4.xml","form_type":"4"}},{"id":3027964,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":45159,"kind":"person","name":"KARBE FRANK","position":1,"cik":"0001276700","reported_name":"KARBE FRANK","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Fin'l & Accounting"}}],"security":"Common Shares","published_at":"2020-09-17T20:20:15.000Z","date":"2020-09-15","kind":"exercise","acquired":true,"shares":750,"price":5.11,"value":3832.5,"ownership":{"direct":true},"balance_after":164220,"source":{"system":"sec-edgar","filing":"0001209191-20-050887","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1276700/000120919120050887/doc4.xml","form_type":"4"}},{"id":3042406,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":45159,"kind":"person","name":"KARBE FRANK","position":1,"cik":"0001276700","reported_name":"KARBE FRANK","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Fin'l & Accounting"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-09-01T20:37:38.000Z","date":"2020-08-31","kind":"exercise","acquired":false,"shares":21150,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Fully vested."}],"balance_after":200144,"derivative":{"exercise_price":5.11,"expiration_date":"2026-09-20","underlying":"Common Shares","underlying_shares":21150},"source":{"system":"sec-edgar","filing":"0001209191-20-048927","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1276700/000120919120048927/doc4.xml","form_type":"4"}},{"id":3042405,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":45159,"kind":"person","name":"KARBE FRANK","position":1,"cik":"0001276700","reported_name":"KARBE FRANK","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Fin'l & Accounting"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-09-01T20:37:38.000Z","date":"2020-08-28","kind":"exercise","acquired":false,"shares":3650,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Fully vested."}],"balance_after":221294,"derivative":{"exercise_price":5.11,"expiration_date":"2026-09-20","underlying":"Common Shares","underlying_shares":3650},"source":{"system":"sec-edgar","filing":"0001209191-20-048927","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1276700/000120919120048927/doc4.xml","form_type":"4"}},{"id":3042404,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":45159,"kind":"person","name":"KARBE FRANK","position":1,"cik":"0001276700","reported_name":"KARBE FRANK","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Fin'l & Accounting"}}],"security":"Common Shares","published_at":"2020-09-01T20:37:38.000Z","date":"2020-08-31","kind":"sale","acquired":false,"shares":21150,"price":20.013,"value":423274.95,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares sold pursuant to a 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The shares were sold at prices ranging from $20.00 to $20.28. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":163470,"source":{"system":"sec-edgar","filing":"0001209191-20-048927","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1276700/000120919120048927/doc4.xml","form_type":"4"}},{"id":3042403,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":45159,"kind":"person","name":"KARBE FRANK","position":1,"cik":"0001276700","reported_name":"KARBE FRANK","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Fin'l & Accounting"}}],"security":"Common Shares","published_at":"2020-09-01T20:37:38.000Z","date":"2020-08-31","kind":"exercise","acquired":true,"shares":21150,"price":5.11,"value":108076.5,"ownership":{"direct":true},"balance_after":184620,"source":{"system":"sec-edgar","filing":"0001209191-20-048927","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1276700/000120919120048927/doc4.xml","form_type":"4"}},{"id":3042402,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":45159,"kind":"person","name":"KARBE FRANK","position":1,"cik":"0001276700","reported_name":"KARBE FRANK","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Fin'l & Accounting"}}],"security":"Common Shares","published_at":"2020-09-01T20:37:38.000Z","date":"2020-08-28","kind":"sale","acquired":false,"shares":3650,"price":20.04,"value":73146.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares sold pursuant to a 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The shares were sold at prices ranging from $20.00 to $20.14. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":163470,"source":{"system":"sec-edgar","filing":"0001209191-20-048927","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1276700/000120919120048927/doc4.xml","form_type":"4"}},{"id":3042401,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":45159,"kind":"person","name":"KARBE FRANK","position":1,"cik":"0001276700","reported_name":"KARBE FRANK","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Fin'l & Accounting"}}],"security":"Common Shares","published_at":"2020-09-01T20:37:38.000Z","date":"2020-08-28","kind":"exercise","acquired":true,"shares":3650,"price":5.11,"value":18651.5,"ownership":{"direct":true},"balance_after":167120,"source":{"system":"sec-edgar","filing":"0001209191-20-048927","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1276700/000120919120048927/doc4.xml","form_type":"4"}},{"id":3049711,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":45159,"kind":"person","name":"KARBE FRANK","position":1,"cik":"0001276700","reported_name":"KARBE FRANK","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Fin'l & Accounting"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-08-21T21:07:45.000Z","date":"2020-08-19","kind":"exercise","acquired":false,"shares":700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Fully vested."}],"balance_after":224944,"derivative":{"exercise_price":5.11,"expiration_date":"2026-09-20","underlying":"Common Shares","underlying_shares":700},"source":{"system":"sec-edgar","filing":"0001209191-20-047968","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1276700/000120919120047968/doc4.xml","form_type":"4"}},{"id":3049710,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":45159,"kind":"person","name":"KARBE FRANK","position":1,"cik":"0001276700","reported_name":"KARBE FRANK","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Fin'l & Accounting"}}],"security":"Common Shares","published_at":"2020-08-21T21:07:45.000Z","date":"2020-08-19","kind":"sale","acquired":false,"shares":700,"price":20,"value":14000.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares sold pursuant to a 10b5-1 trading plan."}],"balance_after":163470,"source":{"system":"sec-edgar","filing":"0001209191-20-047968","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1276700/000120919120047968/doc4.xml","form_type":"4"}},{"id":3049709,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":45159,"kind":"person","name":"KARBE FRANK","position":1,"cik":"0001276700","reported_name":"KARBE FRANK","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Fin'l & Accounting"}}],"security":"Common Shares","published_at":"2020-08-21T21:07:45.000Z","date":"2020-08-19","kind":"exercise","acquired":true,"shares":700,"price":5.11,"value":3577.0,"ownership":{"direct":true},"balance_after":164170,"source":{"system":"sec-edgar","filing":"0001209191-20-047968","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1276700/000120919120047968/doc4.xml","form_type":"4"}},{"id":3132038,"issuer":{"id":110632,"kind":"organization","name":"CHINOOK THERAPEUTICS, INC.","symbol":"KDNY"},"owners":[{"id":45159,"kind":"person","name":"KARBE FRANK","position":1,"cik":"0001276700","reported_name":"KARBE FRANK","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-05-28T20:00:04.000Z","date":"2020-05-05","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the Option will vest quarterly over one year from the grant date of May 5, 2020, such that the shares will be fully vested on the first anniversary of the date of grant."}],"balance_after":30000,"derivative":{"exercise_price":3,"expiration_date":"2030-05-04","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001567619-20-011289","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1435049/000156761920011289/doc1.xml","form_type":"4"}},{"id":3180440,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":45159,"kind":"person","name":"KARBE FRANK","position":1,"cik":"0001276700","reported_name":"KARBE FRANK","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Fin'l & Accounting"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2020-04-07T21:10:49.000Z","date":"2020-04-03","kind":"grant","acquired":true,"shares":183991,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/4 of the common shares underlying this option vest on April 3, 2021, and 1/16 of the common shares underlying this option vest each quarter thereafter, provided the Reporting Person has provided continuous service to the Issuer or its affiliates on each such date."}],"balance_after":183991,"derivative":{"exercise_price":8.08,"expiration_date":"2030-04-02","underlying":"Common Shares","underlying_shares":183991},"source":{"system":"sec-edgar","filing":"0001209191-20-023794","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1276700/000120919120023794/doc4.xml","form_type":"4"}},{"id":3180439,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":45159,"kind":"person","name":"KARBE FRANK","position":1,"cik":"0001276700","reported_name":"KARBE FRANK","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Fin'l & Accounting"}}],"security":"Common Shares","published_at":"2020-04-07T21:10:49.000Z","date":"2020-04-03","kind":"grant","acquired":true,"shares":120146,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Common Shares are to be acquired upon the vesting of certain Restricted Stock Units (\"RSUs\") granted to the Reporting Person. 1/4 of the common shares underlying the RSUs vest on April 3, 2021, and 1/16 of the common shares underlying the RSUs vest each quarter thereafter, provided the Reporting Person has provided continuous service to the Issuer or its affiliates on each such date."}],"balance_after":163470,"source":{"system":"sec-edgar","filing":"0001209191-20-023794","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1276700/000120919120023794/doc4.xml","form_type":"4"}},{"id":3329621,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":45159,"kind":"person","name":"KARBE FRANK","position":1,"cik":"0001276700","reported_name":"KARBE FRANK","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Fin'l & Accounting"}}],"security":"Common Stock","published_at":"2019-12-31T00:13:36.000Z","date":"2019-12-30","kind":"sale","acquired":false,"shares":19701,"price":15.55,"value":306350.55,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares sold by the reporting person to cover the tax obligation realized upon the vesting of restricted stock units previously reported in Table I."}],"balance_after":43324,"source":{"system":"sec-edgar","filing":"0001209191-19-062187","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1276700/000120919119062187/doc4.xml","form_type":"4"}},{"id":3427951,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":45159,"kind":"person","name":"KARBE FRANK","position":1,"cik":"0001276700","reported_name":"KARBE FRANK","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Fin'l & Accounting"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-08-27T20:55:11.000Z","date":"2019-08-26","kind":"grant","acquired":true,"shares":132270,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Each reported acquisition and disposition of an option for the like number of shares consisted of an amendment to an outstanding option, resulting in the deemed cancellation of the \"old\" option and grant of a replacement option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"1/4 of the common shares underlying this option vest on April 5, 2020, and 1/16 of the common shares underlying this option vest each quarter thereafter, provided the Reporting Person has provided continuous service to the Issuer or its affiliates on each such date."}],"balance_after":132270,"derivative":{"exercise_price":7.78,"expiration_date":"2029-04-04","underlying":"Common Shares","underlying_shares":132270},"source":{"system":"sec-edgar","filing":"0001209191-19-047542","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1276700/000120919119047542/doc4.xml","form_type":"4"}},{"id":3427950,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":45159,"kind":"person","name":"KARBE FRANK","position":1,"cik":"0001276700","reported_name":"KARBE FRANK","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Fin'l & Accounting"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-08-27T20:55:11.000Z","date":"2019-08-26","kind":"disposition_to_issuer","acquired":false,"shares":132270,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Each reported acquisition and disposition of an option for the like number of shares consisted of an amendment to an outstanding option, resulting in the deemed cancellation of the \"old\" option and grant of a replacement option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"1/4 of the common shares underlying this option vest on April 5, 2020, and 1/16 of the common shares underlying this option vest each quarter thereafter, provided the Reporting Person has provided continuous service to the Issuer or its affiliates on each such date."}],"balance_after":0,"derivative":{"exercise_price":24.44,"expiration_date":"2029-04-04","underlying":"Common Shares","underlying_shares":132270},"source":{"system":"sec-edgar","filing":"0001209191-19-047542","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1276700/000120919119047542/doc4.xml","form_type":"4"}},{"id":3427949,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":45159,"kind":"person","name":"KARBE FRANK","position":1,"cik":"0001276700","reported_name":"KARBE FRANK","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Fin'l & Accounting"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-08-27T20:55:11.000Z","date":"2019-08-26","kind":"grant","acquired":true,"shares":114690,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Each reported acquisition and disposition of an option for the like number of shares consisted of an amendment to an outstanding option, resulting in the deemed cancellation of the \"old\" option and grant of a replacement option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"1/4 of the common shares underlying this option vested on April 16, 2019, and 1/16 of the common shares underlying this option vest each quarter thereafter, provided the Reporting Person has provided continuous service to the Issuer or its affiliates on each such date. The replacement option provides that the Reporting Person cannot exercise the currently vested portion of the replacement option for 12 months commencing on August 26, 2019, subject to certain exceptions provided by the Reporting Person's applicable option agreement."}],"balance_after":114690,"derivative":{"exercise_price":7.78,"expiration_date":"2028-04-15","underlying":"Common Shares","underlying_shares":114690},"source":{"system":"sec-edgar","filing":"0001209191-19-047542","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1276700/000120919119047542/doc4.xml","form_type":"4"}},{"id":3427948,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":45159,"kind":"person","name":"KARBE FRANK","position":1,"cik":"0001276700","reported_name":"KARBE FRANK","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Fin'l & Accounting"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-08-27T20:55:11.000Z","date":"2019-08-26","kind":"disposition_to_issuer","acquired":false,"shares":114690,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Each reported acquisition and disposition of an option for the like number of shares consisted of an amendment to an outstanding option, resulting in the deemed cancellation of the \"old\" option and grant of a replacement option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"1/4 of the common shares underlying this option vested on April 16, 2019, and 1/16 of the common shares underlying this option vest each quarter thereafter, provided the Reporting Person has provided continuous service to the Issuer or its affiliates on each such date. The replacement option provides that the Reporting Person cannot exercise the currently vested portion of the replacement option for 12 months commencing on August 26, 2019, subject to certain exceptions provided by the Reporting Person's applicable option agreement."}],"balance_after":0,"derivative":{"exercise_price":21.87,"expiration_date":"2028-04-15","underlying":"Common Shares","underlying_shares":114690},"source":{"system":"sec-edgar","filing":"0001209191-19-047542","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1276700/000120919119047542/doc4.xml","form_type":"4"}},{"id":3427947,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":45159,"kind":"person","name":"KARBE FRANK","position":1,"cik":"0001276700","reported_name":"KARBE FRANK","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Fin'l & Accounting"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-08-27T20:55:11.000Z","date":"2019-08-26","kind":"grant","acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Each reported acquisition and disposition of an option for the like number of shares consisted of an amendment to an outstanding option, resulting in the deemed cancellation of the \"old\" option and grant of a replacement option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"1/4 of the shares underlying the option vested on May 15, 2018, and 1/16 of the common shares underlying this option vest each quarter thereafter, subject to the Reporting Person providing continuous service to the Issuer on each such date. The replacement option provides that the Reporting Person cannot exercise the currently vested portion of the replacement option for 12 months commencing on August 26, 2019, subject to certain exceptions provided by the Reporting Person's applicable option agreement."}],"balance_after":200000,"derivative":{"exercise_price":7.78,"expiration_date":"2027-05-14","underlying":"Common Shares","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001209191-19-047542","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1276700/000120919119047542/doc4.xml","form_type":"4"}},{"id":3427946,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":45159,"kind":"person","name":"KARBE FRANK","position":1,"cik":"0001276700","reported_name":"KARBE FRANK","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Fin'l & Accounting"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-08-27T20:55:11.000Z","date":"2019-08-26","kind":"disposition_to_issuer","acquired":false,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Each reported acquisition and disposition of an option for the like number of shares consisted of an amendment to an outstanding option, resulting in the deemed cancellation of the \"old\" option and grant of a replacement option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"1/4 of the shares underlying the option vested on May 15, 2018, and 1/16 of the common shares underlying this option vest each quarter thereafter, subject to the Reporting Person providing continuous service to the Issuer on each such date. The replacement option provides that the Reporting Person cannot exercise the currently vested portion of the replacement option for 12 months commencing on August 26, 2019, subject to certain exceptions provided by the Reporting Person's applicable option agreement."}],"balance_after":0,"derivative":{"exercise_price":12.68,"expiration_date":"2027-05-14","underlying":"Common Shares","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001209191-19-047542","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1276700/000120919119047542/doc4.xml","form_type":"4"}},{"id":3427945,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":45159,"kind":"person","name":"KARBE FRANK","position":1,"cik":"0001276700","reported_name":"KARBE FRANK","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Fin'l & Accounting"}}],"security":"Common Shares","published_at":"2019-08-27T20:55:11.000Z","date":"2019-08-26","kind":"grant","acquired":true,"shares":55025,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Common Shares are to be acquired upon the vesting of certain Restricted Stock Units (\"RSUs\") granted to the Reporting Person. The RSUs shall vest as follows: (i) 1/3 of the total shares subject to the RSUs shall vest at the later occurrence of (a) the achievement of certain milestones and (b) the first anniversary of the grant date; and (ii) 2/3 of the total shares subject to the RSUs shall vest as follows: 1/8 vesting on the first anniversary of the grant date and 7/8 vesting in seven even installments each quarter thereafter, provided the Reporting Person has provided continuous service to the Issuer or its affiliates on each such date."}],"balance_after":63025,"source":{"system":"sec-edgar","filing":"0001209191-19-047542","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1276700/000120919119047542/doc4.xml","form_type":"4"}},{"id":3493858,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":45159,"kind":"person","name":"KARBE FRANK","position":1,"cik":"0001276700","reported_name":"KARBE FRANK","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Fin'l & Accounting"}}],"security":"Common Shares","published_at":"2019-06-11T20:55:49.000Z","date":"2019-06-11","kind":"purchase","acquired":true,"shares":8000,"price":9.1,"value":72800.0,"ownership":{"direct":true},"balance_after":8000,"source":{"system":"sec-edgar","filing":"0001209191-19-036115","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1276700/000120919119036115/doc4.xml","form_type":"4"}},{"id":3525944,"issuer":{"id":110632,"kind":"organization","name":"CHINOOK THERAPEUTICS, INC.","symbol":"KDNY"},"owners":[{"id":45159,"kind":"person","name":"KARBE FRANK","position":1,"cik":"0001276700","reported_name":"KARBE FRANK","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-05-15T19:05:06.000Z","date":"2019-05-14","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the Option will vest quarterly over one year from the grant date of May 14, 2019, such that the shares will be fully vested on the first anniversary of the date of grant."}],"balance_after":30000,"derivative":{"exercise_price":3.29,"expiration_date":"2029-05-13","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001567619-19-011356","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1435049/000156761919011356/doc1.xml","form_type":"4"}},{"id":3552097,"issuer":{"id":110632,"kind":"organization","name":"CHINOOK THERAPEUTICS, INC.","symbol":"KDNY"},"owners":[{"id":45159,"kind":"person","name":"KARBE FRANK","position":1,"cik":"0001276700","reported_name":"KARBE FRANK","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Initial Option Grant","published_at":"2019-04-19T16:15:12.000Z","date":"2019-04-18","kind":"grant","acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the initial option grant vest 1/3 after the first year, the remaining shares will vest quarterly in years two and three following the grant date of April 18, 2019."}],"balance_after":60000,"derivative":{"exercise_price":3.38,"expiration_date":"2029-04-17","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001567619-19-008985","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1435049/000156761919008985/doc1.xml","form_type":"4"}},{"id":3559251,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":45159,"kind":"person","name":"KARBE FRANK","position":1,"cik":"0001276700","reported_name":"KARBE FRANK","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Fin'l & Accounting"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-04-09T22:14:30.000Z","date":"2019-04-05","kind":"grant","acquired":true,"shares":132270,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/4 of the common shares underlying this option vest on April 5, 2020, and 1/16 of the common shares underlying this option vest at the end of each quarter thereafter, provided the Reporting Person has provided continuous service to the Issuer or its affiliates on each such date."}],"balance_after":132270,"derivative":{"exercise_price":24.44,"expiration_date":"2029-05-04","underlying":"Common Stock","underlying_shares":132270},"source":{"system":"sec-edgar","filing":"0001209191-19-024132","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1276700/000120919119024132/doc4.xml","form_type":"4"}},{"id":3960827,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":45159,"kind":"person","name":"KARBE FRANK","position":1,"cik":"0001276700","reported_name":"KARBE FRANK","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Fin'l & Accounting"}}],"security":"Stock Option (Right to Buy)","published_at":"2018-04-18T22:40:36.000Z","date":"2018-04-16","kind":"grant","acquired":true,"shares":114690,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/4 of the common shares underlying this option vest on April 16, 2019, and 1/16 of the common shares underlying this option vest at the end of each quarter thereafter measured from April 16, 2019, provided the Reporting Person has provided continuous service to the Issuer or its affiliates on each such date."}],"balance_after":114690,"derivative":{"exercise_price":21.87,"expiration_date":"2028-04-15","underlying":"Common Shares","underlying_shares":114690},"source":{"system":"sec-edgar","filing":"0001209191-18-025453","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1276700/000120919118025453/doc4.xml","form_type":"4"}},{"id":4273475,"issuer":{"id":4953,"kind":"organization","name":"Arbutus Biopharma Corp","symbol":"ABUS"},"owners":[{"id":45159,"kind":"person","name":"KARBE FRANK","position":1,"cik":"0001276700","reported_name":"KARBE FRANK","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-06-23T20:01:20.000Z","date":"2017-06-21","kind":"grant","acquired":true,"shares":22000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Immediately exercisable."}],"balance_after":22000,"derivative":{"exercise_price":3.55,"expiration_date":"2027-06-21","underlying":"Common Stock","underlying_shares":22000},"source":{"system":"sec-edgar","filing":"0001209191-17-041627","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1447028/000120919117041627/doc4.xml","form_type":"4"}},{"id":4315344,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":45159,"kind":"person","name":"KARBE FRANK","position":1,"cik":"0001276700","reported_name":"KARBE FRANK","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Fin'l & Accounting"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-05-17T21:09:57.000Z","date":"2017-05-15","kind":"grant","acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares underlying the option vest and become exercisable on May 15, 2018; the balance of the shares vest and become exercisable in a series of twelve (12) successive equal quarterly installments measured from May 15, 2018, subject to the Reporting Person providing continuous service to the Issuer on each such date."}],"balance_after":200000,"derivative":{"exercise_price":12.68,"expiration_date":"2027-05-14","underlying":"Common Shares","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001209191-17-033224","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1276700/000120919117033224/doc4.xml","form_type":"4"}}]}